Chengheng Liao

12PUBLICATIONS
61CO-AUTHORS
Molecular targetsCancer cell biologyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Sep 23, 2026
SPOP-mediated ZMYND8 ubiquitination and phase separation exclusion drives mTOR inhibitor resistance in kidney cancer.

|Jul 17, 2026
A single chromosome 3p break initiates clear cell renal cell carcinoma evolution.

|Feb 04, 2026
ZNF395 Is a Hypoxia-Responsive Regulator of Mitochondrial Glutaminolysis in Clear Cell Renal Cell Carcinoma.

Joanna Koh, Chengheng Liao, Michelle Shu Wen Ng

|Feb 11, 2025
BBOX1 restrains TBK1-mTORC1 oncogenic signaling in clear cell renal cell carcinoma.

Chengheng Liao, Lianxin Hu, Liwei Jia

|May 02, 2024
Von Hippel-Lindau protein signalling in clear cell renal cell carcinoma.

Chengheng Liao, Lianxin Hu, Qing Zhang

|Nov 08, 2022
Histone H3 proline 16 hydroxylation regulates mammalian gene expression.

Xijuan Liu, Jun Wang, Joshua A Boyer

Pageof 2

Frequent Collaborators

8 joint publications

Qing Zhang

4 joint publications

Lianxin Hu

4 joint publications

Jeremy M Simon

2 joint publications

Ralph J DeBerardinis